Traveler’s Diarrhea – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Traveler’s Diarrhea – Drugs In Development, 2024 report and make more profitable business decisions.
Traveler’s diarrhea occurs within 10 days of travel to an area with poor public hygiene. The most common illness in travelers, it is caused by drinking water or eating food that contains bacteria, viruses, or parasites. Most traveler’s diarrhea is from bacteria. It often goes away in a few days. Often, the only treatment is fluid replacement.
The Traveler’s Diarrhea drugs in development market research report provide comprehensive information on the therapeutics under development for Traveler’s Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Traveler’s Diarrhea and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Traveler's Diarrhea | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Traveler’s Diarrhea therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Traveler’s Diarrhea pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Traveler’s Diarrhea treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Angelini Pharma SpACosmo Pharmaceuticals NV
Immuron Ltd
Lumen Bioscience Inc
Napo Pharmaceuticals Inc
Prokarium Ltd
Scandinavian Biopharma Holding AB
The Institute of Medical Science The University of Tokyo
University of Bergen
Vanda Pharmaceuticals Inc
Vanderbilt University
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Traveler's Diarrhea reports